1. Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
   Jingpei Li et al, 2020, Frontiers in Oncology CrossRef
2. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases
   Dimitra Stefanou et al, 2016, Oncology Letters CrossRef
3. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
   null null et al, 2018, International Journal of Clinical Oncology CrossRef
4. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis
   Musen Wang et al, 2021, Medicine CrossRef
5. Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer
   Hiroaki Ikesue et al, 2015, Biological & Pharmaceutical Bulletin CrossRef
6. Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
   Takayasu Kurata et al, 2017, Genes & Cancer CrossRef
7. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
   Toshirou Fukushima et al, 2018, Cancer Chemotherapy and Pharmacology CrossRef
8. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
   Yasuhiro Tsutani et al, 2018, BMC Cancer CrossRef